You have 9 free searches left this month | for more free features.

ofatumumab

Showing 1 - 25 of 81

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Tampa (High Dose Methylprednisolone (HDMP), Ofatumumab,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • High Dose Methylprednisolone (HDMP)
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 12, 2023

CLL, SLL Trial in Boston (Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab)

Terminated
  • CLL
  • SLL
  • Ofatumumab
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 30, 2023

Leukemia, Lymphoma Trial in Houston (Ofatumumab)

Active, not recruiting
  • Leukemia
  • Lymphoma
  • Ofatumumab
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 9, 2022

Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia) Trial run by the National Heart, Lung, and Blood Institute

Active, not recruiting
  • Small Lymphocytic Lymphoma
  • CLL (Chronic Lymphocytic Leukemia)
  • Fludarabine Phosphate
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022

Multiple Sclerosis Trial in Germany (Ofatumumab)

Active, not recruiting
  • Multiple Sclerosis
  • Ofatumumab
  • Berlin, Germany
  • +5 more
Jan 13, 2023

Ocrelizumab and Ofatumumab Administration in Relapsing Multiple

Completed
  • Relapsing Forms of Multiple Sclerosis
  • Lutherville, Maryland
  • +1 more
Oct 19, 2022

Chronic GVHD Trial in United States (Ofatumumab)

Completed
  • Chronic Graft Versus Host Disease
  • Ofatumumab
  • Phoenix, Arizona
  • +3 more
Sep 30, 2022

Neuromyelitis Optica Spectrum Disorder Trial in Xi'an (Ofatumumab)

Recruiting
  • Neuromyelitis Optica Spectrum Disorder
  • Ofatumumab
  • Xi'an, Shaanxi, China
    Tangdu Hospital
Aug 16, 2022

Immune Cells and Meningeal Lymphatic Drainage in Demyelinating

Recruiting
  • Multiple Sclerosis
  • +2 more
  • Ofatumumab
  • Tianjin, Tianjin, China
    Tianjin Medical University General Hospital
Oct 19, 2022

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)

Completed
  • Non-Hodgkin's Lymphoma
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate)

Recruiting
  • Relapsing Multiple Sclerosis (RMS)
  • Ofatumumab
  • +2 more
  • Phoenix, Arizona
  • +3 more
Jul 20, 2022

Relapse Remitting Multiple Sclerosis Trial in United States (Ofatumumab)

Recruiting
  • Relapse Remitting Multiple Sclerosis
  • Ofatumumab
  • Chandler, Arizona
  • +16 more
Jan 13, 2023

Relapsing Multiple Sclerosis Trial in Japan, Russian Federation (Ofatumumab, Matching of ofatumumab)

Completed
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Matching placebo of ofatumumab
  • Toon-city, Ehime, Japan
  • +13 more
Apr 27, 2022

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ofatumumab
  • Los Angeles, California
    University of Southern California
Feb 3, 2022

Chronic Lymphocytic Leukemia Trial in Houston (Ofatumumab)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Ofatumumab
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 23, 2022

Chronic Lymphocytic Leukemia Trial in Spain (Ofatumumab)

Completed
  • Chronic Lymphocytic Leukemia
  • Ofatumumab
  • Badalona, Spain
  • +8 more
May 2, 2022

Diffuse Large Cell Lymphoma Relapsed/Refractory Trial in San Francisco (Ofatumumab, Etoposide, Cytarabine)

Completed
  • Diffuse Large Cell Lymphoma Relapsed/Refractory
  • Ofatumumab
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jun 5, 2022

Multiple Sclerosis (MS) Trial in Worldwide (Fingolimod, Ofatumumab, Siponimod)

Recruiting
  • Multiple Sclerosis (MS)
  • Little Rock, Arkansas
  • +55 more
Jan 13, 2023

Relapsing Multiple Sclerosis Trial in Puerto Rico, United States (Ofatumumab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Birmingham, Alabama
  • +16 more
Mar 22, 2022

Relapsing Multiple Sclerosis Trial in United States (Quadrivalent influenza vaccine, Ofatumumab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Quadrivalent influenza vaccine
  • Ofatumumab
  • Phoenix, Arizona
  • +3 more
Aug 30, 2021

Relapsing Multiple Sclerosis Trial in Boston (Ofatumumab, [F-18]PBR06)

Recruiting
  • Relapsing Multiple Sclerosis
  • Boston, Massachusetts
    Partners MS Center, 60 Fenwood Road
Jul 20, 2021

Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma Trial in

Active, not recruiting
  • Stage I Mantle Cell Lymphoma
  • +4 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Buffalo, New York
  • +1 more
Mar 9, 2022

Diffuse Large B Cell Lymphoma Trial in Poland (Ofatumumab, Etoposide, Ifosfamid)

Completed
  • Diffuse Large B Cell Lymphoma
  • Ofatumumab
  • +7 more
  • Wrocław, Dolnośląskie, Poland
  • +7 more
Dec 23, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Tampa (High Dose Methylprednisolone (HDMP), Ofatumumab,

Completed
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • High Dose Methylprednisolone (HDMP)
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Apr 2, 2021